02117nam 2200637 a 450 991046166980332120211104233457.03-11-096049-410.1515/9783110960495(CKB)2670000000249711(EBL)3041122(SSID)ssj0000594900(PQKBManifestationID)11375249(PQKBTitleCode)TC0000594900(PQKBWorkID)10549068(PQKB)11306224(MiAaPQ)EBC3041122(WaSeSS)Ind00009632(DE-B1597)49626(OCoLC)979955957(DE-B1597)9783110960495(PPN)175494711(Au-PeEL)EBL3041122(CaPaEBR)ebr10591471(OCoLC)922944063(EXLCZ)99267000000024971120030124d2002 uy 0laturnn#---|u||utxtccrCommentum in Ciceronis rhetorica[electronic resource] /Grillius ; edidit Rainer JakobiReprint 2011München Saurc20021 online resource (112 p.)Bibliotheca scriptorum Graecorum et Romanorum TeubnerianaDescription based upon print version of record.3-598-71230-8 Includes bibliographical references and index.Front matter --PRAEFATIO --SIGLA --OPERA IMPRESSA, QVAE IN APPARATV LAVDANTVR --COMMENTVM IN CICERONIS RHETORICA --INDEX NOMINVM ET LOCORVMBibliotheca Scriptorum Graecorum et Romanorum TeubnerianaInvention (Rhetoric)Early works to 1800Rhetoric, AncientElectronic books.Invention (Rhetoric)Rhetoric, Ancient.Grilliusgrammarian,5th cent.?186238Jakobi Rainer282917MiAaPQMiAaPQMiAaPQBOOK9910461669803321Commentum in Ciceronis rhetorica1901164UNINA03513nam 2200661 a 450 991078129950332120230725051815.00-309-20959-51-283-01910-897866130191030-309-15890-7(CKB)2550000000032026(EBL)3378748(SSID)ssj0000507437(PQKBManifestationID)11344055(PQKBTitleCode)TC0000507437(PQKBWorkID)10562131(PQKB)10436788(MiAaPQ)EBC3378748(Au-PeEL)EBL3378748(CaPaEBR)ebr10454969(CaONFJC)MIL301910(OCoLC)923283190(EXLCZ)99255000000003202620110414d2011 uy 0engurcn|||||||||txtccrBuilding a national framework for the establishment of regulatory science for drug development[electronic resource] workshop summary /Institute of Medicine of the National Academies ; Yeonwoo Lebovitz, Rebecca A. English, and Anne B. Claiborne, rapporteursWashington, D.C. National Academies Press20111 online resource (95 p.)"Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy."0-309-15889-3 Includes bibliographical references.""Front Matter""; ""Reviewers""; ""Contents""; ""Figures and Boxes""; ""Acronyms""; ""Preface""; ""1 Introduction""; ""2 Defining Regulatory Science""; ""3 The Urgent Need for Regulatory Science""; ""4 Barriers to Enhanced Regulatory Science""; ""5 Potential Models for Building a Regulatory Science Infrastructure""; ""6 Challenges in Engaging the Public Policy Community""; ""7 Envisioning Successful Regulatory Science at FDA""; ""8 Considering Next Steps""; ""References""; ""Appendix A: Agenda""; ""Appendix B: Participant Biographies"""The Food and Drug Administration (FDA) is tasked with ensuring the safety and effectiveness of medicine. FDA's science base must be strong enough to make certain that regulatory decisions are based on the best scientific evidence. The IOM held a public workshop on February 26, 2010, to examine the state of regulatory science and to consider approaches for enhancing it."--Publisher's description.Pharmaceutical policyUnited StatesCongressesDrug developmentGovernment policyUnited StatesCongressesPharmaceutical industryGovernment policyUnited StatesCongressesPharmaceutical policyDrug developmentGovernment policyPharmaceutical industryGovernment policy615.1Lebovitz Yeonwoo1521511English Rebecca A1471734Claiborne Anne B1471735Institute of Medicine (U.S.).Forum on Drug Discovery, Development, and Translation.Institute of Medicine (U.S.).Board on Health Sciences Policy.Building a National Framework for the Establishment of Regulatory Science for Drug Development(2010 :Washington, D.C.)MiAaPQMiAaPQMiAaPQBOOK9910781299503321Building a national framework for the establishment of regulatory science for drug development3788760UNINA